Weight loss drugs have taken the world by storm - dominating headlines, social media, and conversations across healthcare. Once class in particular, the Glucagon-like peptide 1 agonists like semaglutide or Ozempic, have become a cutting-edge therapy, celebrated not only for their efficacy in weight loss but also their benefits in kidney and heart disease protection.

But what if their impact goesBEYOND weight loss?